Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: A UK healthcare perspective

ClinicoEconomics and Outcomes Research

Volumn 7, Issue , 2015, Pages 235-247

  Régnier, Stephane A ^a   Malcolm, William ^b   Haig, Jennifer ^c   Xue, Weiguang ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Novartis Pharmaceuticals UK Ltd   (United Kingdom)

^c OPTUM   (United States)

Author keywords

Cost utility; Health states; Macula; Markov model; Retina

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB;

ADULT; AGED; ARTICLE; ATTITUDE TO HEALTH; CLINICAL STUDY; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETIC MACULAR EDEMA; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; TREATMENT DURATION; UNITED KINGDOM; VERY ELDERLY; VISUAL ACUITY; VISUAL IMPAIRMENT; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84930669024     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S82556     Document Type: Article

References (49)

1. Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2012;12(4):346–354.
2. Boscia F. Current approaches to the management of diabetic retinopathy and diabetic macular oedema. Drugs. 2010;70(16):2171–2200.
3. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010; 376(9735):124–136.
4. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Dia­betes Care. 2003;26(9):2653–2664.
5. Davidov E, Breitscheidel L, Clouth J, Reips M, Happich M. Diabetic retinopathy and health-related quality of life. Graefes Arch Clin Exp Ophthalmol. 2009;247(2):267–272.
6. Lamoureux EL, Tai ES, Thumboo J, et al. Impact of diabetic retinopathy on vision-specific function. Ophthalmology. 2010;117(4):757–765.
7. Matza LS, Rousculp MD, Malley K, Boye KS, Oglesby A. The lon­gitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathy. Health Qual Life Outcomes. 2008;6:95.
8. Chen E, Looman M, Laouri M, et al. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin. 2010;26(7): 1587–1597.
9. Delcourt C, Sivaprasad S, Bandello F, et al. Prevalence of diabetic macu­lar edema (DME) in Europe: the Pan European Prevalence Assessment of DME with Visual Impairment (PREVAIL) study. [Submitted].
10. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1): 4–14.
11. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009;54(1):1–32.
12. Klaassen I, Van Noorden CJ, Schlingemann RO. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res. 2013;34:19–48.
13. Zhang X, Bao S, Hambly BD, Gillies MC. Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy. Int J Biochem Cell Biol. 2009;41(12):2368–2371.
14. Nguyen QD, Brown DM, Marcus DM, et al; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801.
15. Brown DM, Nguyen QD, Marcus DM, et al; RISE and RIDE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macu­lar edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013–2022.
16. Mitchell P, Bandello F, Schmidt-Erfurth U, et al; RESTORE Study Group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615–625.
17. European Medicines Agency. Assessment Report for Lucentis (Ranibizumab). EMA/13901/2011; 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000715/WC500101009.pdf. Accessed October 7, 2014.
18. European Medicines Agency. Assessment Report for Eylea (Aflibercept). EMA/430291/2014; 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/002392/WC500172846.pdf. Accessed October 7, 2014.
19. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–2254.
20. Mitchell P, Annemans L, Gallagher M, et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol. 2012;96(5):688–693.
21. National Institute for Health and Care Excellence. Ranibizumab for Treating Diabetic Macular Oedema (Rapid Review of Technology Appraisal Guidance 237) [TA274]; 2013. Available from: http://www.nice.org.uk/guidance/ta274. Accessed October 7, 2014.
22. Klein R, Klein BE, Moss SE, DeMets DL, Kaufman I, Voss PS. Prevalence of diabetes mellitus in southern Wisconsin. Am J Epidemiol. 1984;119(1):54–61.
23. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102(4):520–526.
24. Regnier S, Malcolm W, Allen F, Wright J, Bezlyak V. Efficacy of anti-VEGF and laser photocoagulation in the treatment of visual impair­ment due to diabetic macular edema: a systematic review and network meta-analysis. PLoS One. 2014;9(7):e102309.
25. Pruente C, Group RS. Efficacy and safety of ranibizumab in two treat-and-extend versus pro-re-nata regimes in patients with visual impairment due to diabetic macular edema: 24-month results of RETAIN study. Invest Ophthalmol Vis Sci. 2014;55:E-Abstract 1700.
26. Bressler NM, Chang TS, Suñer IJ, et al; MARINA and ANCHOR Research Groups. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology. 2010;117(4):747.e–756.e.
27. Czoski-Murray C, Carlton J, Brazier J, Young T, Papo NL, Kang HK. Valuing condition-specific health states using simulation contact lenses. Value Health. 2009;12(5):793–799.
28. National Institute for Health and Care Excellence. Aflibercept Solution for Injection for Treating Wet Age-Related Macular Degeneration [TA294]; 2013. Available from: http://www.nice.org.uk/guidance/ta294. Accessed October 7, 2014.
29. Elman MJ, Qin H, Aiello LP, Beck RW, et al; Intravitreal ranibi­zumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology. 2012;119(11):2312–2318.
30. European Medicines Agency. Lucentis: EPAR – Product Informa­tion; 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000715/WC500043546.pdf. Accessed March 4, 2015.
31. Campochiaro PA, Sophie R, Pearlman J, et al; RETAIN Study Group. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014;121(1): 209–219.
32. Claxton K, Martin S, Soares M, et al. Methods for the Estimation of the NICE Cost Effectiveness Threshold. New York: University of York, Centre for Health Economics; 2013.
33. Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
34. Jusufbegovic D, Mugavin MO, Schaal S. Evolution of controlling diabetic retinopathy: changing trends in the management of diabetic macular edema at a single institution over the past decade. Retina. Epub January 14, 2015.
35. Petrella RJ, Blouin J, Davies B, Barbeau M. Prevalence, demograph­ics, and treatment characteristics of visual impairment due to diabetic macular edema in a representative Canadian cohort. J Ophthalmol. 2012;2012:159167.
36. Lang GE, Berta A, Eldem BM, et al; RESTORE Extension Study Group. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study. Ophthalmology. 2013;120(10):2004–2012.
37. Schmid MK, Bachmann LM, Fäs L, Kessels AG, Job OM, Thiel MA. Efficacy and adverse events of aflibercept, ranibizumab and bevaci­zumab in age-related macular degeneration: a trade-off analysis. Br J Ophthalmol. 2015;99(2):141–146.
38. European Medicines Agency. Eylea: EPAR – Product Information; 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002392/WC500135815.pdf. Accessed March 5, 2014.
39. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology. 1987;94(7):761–774.
40. Schmidt-Erfurth U, Lang GE, Holz FG, et al; RESTORE Extension Study Group. Three-year outcomes of individualized ranibizumab treat­ment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology. 2014;121(5):1045–1053.
41. Efficacy and safety of ranibizumab monotherapy or combined with laser versus laser monotherapy in diabetic macular edema: the RESPOND study. Can J Ophthalmol. 2015. [In press].
42. Bakshi NK. Update on the VIVID-DME and VISTA-DME tri­als. Ophthalmol Sci Update; 2014. Available from: http://www.ophthalmologyupdate.ca/crus/230-015%206-pages%20English.pdf. Accessed October 15, 2014.
43. UK Department of Health. 2011–2012 NHS Reference Costs; 2014. Available from: https://www.gov.uk/government/publications/nhs-reference-costs-financial-year-2011-to-2012. Accessed October 7, 2014.
44. Shyangdan D, Cummins E, Lois N, Royle P, Waugh N. Dexamethasone Implants in the Treatment of Macular Oedema Due to Retinal Vein Occlusion: A Single Technology Appraisal. Aberdeen Health Technology Assessment Group 2010; 2014. Available from: http://www.nice.org.uk/nicemedia/live/13037/52883/52883.pdf. Accessed October 7, 2014.
45. Hospital and Community Health Services. HCHS Pay and Prices Series 2010–2011; 2014. Available from: http://www.info.doh.gov.uk/doh/finman.nsf/af3d43e36a4c8f8500256722005b77f8/276315c0677bf5478025796b00418a4d?OpenDocument. Accessed October 16, 2014.
46. Personal Social Services Research Unit. Unit Costs of Health and Social Care 2011; 2014. Available from: http://www.pssru.ac.uk/project-pages/unit-costs/2011/. Accessed October 7, 2014.
47. Personal Social Services Research Unit. Unit Costs of Health and Social Care 2003; 2014. Available from: http://www.pssru.ac.uk/project-pages/unit-costs/2003/. Accessed October 7, 2014.
48. McCrone P, Dhanasiri S, Patel A, Knapp M, Lawton-Smith S. Paying the Price (2008): the Cost of Mental Health Care in England to 2026; 2014. Available from: http://www.kingsfund.org.uk/publications/paying-price. Accessed October 7, 2014.
49. Appleby J, Poteliakhoff E, Shah K, Devlin N. Using patient-reported outcome measures to estimate cost-effectiveness of hip replacements in English hospitals. J R Soc Med. 2013;106(8):323–331.